We manage the global IP portfolio for Novelis Inc., an $11.1 billion dollar company and the world’s largest rolled aluminum producer in terms of volume shipped. Novelis’ patent portfolio consists of more than 200 patent families. We coordinated the company’s global patent strategy, identified new foreign patent counsel, accelerated prosecution of applications throughout the world, and assisted in European patent oppositions. In addition to managing the company’s global IP portfolio, we are also working with Novelis on corporate matters, licensing, trade secrets, and federal grants.

Assisted lead counsel for the plaintiff, Porex Corporation, a leader in the development and manufacturing of porous plastic and porous fiber products, in patent infringement litigation. Soon after filing the suit, we filed a motion for preliminary injunction, engaged in expedited discovery and had a hearing date for an evidentiary hearing on the motion. At the same time the case was proceeding, our client was engaged in confidential negotiations for an asset sale transaction that included the operating business and the patent involved in the litigation that made the resolution of the case an important consideration in closing that transaction. Against that backdrop, we were able to negotiate a settlement of the lawsuit with the defendant on terms that pleased not only our client but the third party with which our client was negotiating and enabled our client to close its significant asset sale transaction.

Advises Porex Corporation in developing and coordinating global patent strategy, preparing and prosecuting patent applications in the areas of medical devices, polymer chemistry and inorganic chemistry for medical implants, filters, nibs, detection devices and wicks, assisting in due diligence for intellectual property matters, and managing its trademark portfolio.

Assisted lead counsel in representing Biotest AG (Biotest), a German publicly traded biotechnology company, in signing a global License, Development and Commercialization Agreement with Abbott Laboratories for the further development and commercialization of Biotest’s BT-061, a novel anti-CD4 antibody for the treatment of Rheumatoid Arthritis (RA) and psoriasis. In connection with the deal, Biotest will receive an upfront payment of $85 million, and upon completion of certain milestones, additional payments totaling $395 million, plus royalties.

Represents Prometic Life Sciences Inc., on intellectual property issues including design and implementation of global patent strategy, preparing and prosecuting patent applications involving bacterial ribonucleic acid cell wall compositions and their uses and assisting in IP due diligence.

Represents HDL Therapeutics Inc., on intellectual property issues including design and implementation of global patent strategy, preparing and prosecuting patent applications involving HDL particle derivatives with reduced lipid content and assisting in IP due diligence.